[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Meiby et al., 2013 - Google Patents

Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90

Meiby et al., 2013

View HTML
Document ID
14494670988616226772
Author
Meiby E
Simmonite H
le Strat L
Davis B
Matassova N
Moore J
Mrosek M
Murray J
Hubbard R
Ohlson S
Publication year
Publication venue
Analytical chemistry

External Links

Snippet

The increasing use of fragment-based lead discovery (FBLD) in industry as well as in academia creates a high demand for sensitive and reliable methods to detect the binding of fragments to act as starting points in drug discovery programs. Nuclear magnetic resonance …
Continue reading at www.diva-portal.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means

Similar Documents

Publication Publication Date Title
Meiby et al. Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90
Resnick et al. Rapid covalent-probe discovery by electrophile-fragment screening
Bach et al. Light-activatable, 2, 5-disubstituted tetrazoles for the proteome-wide profiling of aspartates and glutamates in living bacteria
Guo et al. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Dalvit et al. Ligand-based fluorine NMR screening: principles and applications in drug discovery projects
Renaud et al. Biophysics in drug discovery: impact, challenges and opportunities
Maple et al. Automated protein–ligand interaction screening by mass spectrometry
Powell et al. Selective degradation of GSPT1 by cereblon modulators identified via a focused combinatorial library
Pomerantz et al. Profiling the dynamic interfaces of fluorinated transcription complexes for ligand discovery and characterization
Rabuck et al. Activation state-selective kinase inhibitor assay based on ion mobility-mass spectrometry
Simard et al. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors
Millward et al. Iterative in situ click chemistry assembles a branched capture agent and allosteric inhibitor for Akt1
Robers et al. Quantifying target occupancy of small molecules within living cells
Cabrera et al. Comparative analysis of mass-spectrometry-based proteomic methods for protein target discovery using a one-pot approach
Gilbert et al. Profiling sulfur (VI) fluorides as reactive functionalities for chemical biology tools and expansion of the ligandable proteome
Cordier et al. Direct Observation of Cα− Hα⊙⊙⊙ OC Hydrogen Bonds in Proteins by Interresidue h3 J CαC ‘Scalar Couplings
Moschen et al. Measurement of Ligand–Target Residence Times by 1H Relaxation Dispersion NMR Spectroscopy
Roehrl et al. Discovery of small-molecule inhibitors of the NFAT− calcineurin interaction by competitive high-throughput fluorescence polarization screening
Xu et al. Mass spectrometry-and lysine amidination-based protocol for thermodynamic analysis of protein folding and ligand binding interactions
Ma et al. Chemo-selection strategy for limited proteolysis experiments on the proteomic scale
Ciccimaro et al. Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry
Sameshima et al. Discovery of an irreversible and cell-active BCL6 inhibitor selectively targeting Cys53 located at the protein–protein interaction interface
Fischer et al. Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS)
George et al. Comparison of quantitative mass spectrometric methods for drug target identification by thermal proteome profiling
Li et al. High-throughput kinetic characterization of irreversible covalent inhibitors of KRASG12C by intact protein MS and targeted MRM